09/02/2022

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

The Ad26.COV2.S vaccine was highly effective against severe–critical coronavirus disease 2019 (Covid-19), hospitalization, and death in the primary phase 3 efficacy analysis.

Matéria original

Anterior

Monoclonal antibody therapies in the management of SARS-CoV-2 infection
Próxima

Severe COVID-19 during pregnancy treated with pulse corticosteroid therapy and mid-trimester termination: A case report